Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants (ABSA)
Firm commitment from an investor for €2.7m, supplemented by indications of interest already exceeding the minimum targeted amount
Lock-up commitment from the EIB (2 years) and a standstill agreement from the Company (6 months) to ensure capital stability
Alignment of all shareholder interests through the free allocation of warrants (BSA) to existing shareholders
Paris and Boston, October 8, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today specifies the terms of its proposed capital increase (the “Capital Increase”) as part of its safeguard plan, which was approved by a majority of the classes of affected parties as announced on October 6.
The Capital Increase, for a total amount between €5 million and €8 million, will be carried out through a private placement of shares with attached warrants (“ABSA”) to institutional investors, family offices, and business angels known for their expertise and long-term investment approach in the healthcare and MedTech sectors.
Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, commented: “The favorable vote on our draft safeguard plan by a majority of classes was the first key milestone on the way to a much stronger financial structure. The second key step, the financing of the plan, is shaping up very nicely. The fact that we have already received firm commitments and indications of interest covering the minimum amount of the transaction demonstrates the support of long-term investors for the new chapter we are opening. With this operation, we will have the means to achieve our most important goal: to become a profitable company, capable of sustainable self-financing. This is a transformative prospect for the Company, its teams, and all its shareholders.”
